<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item><item key="slug">effect-of-protease-resistant-pml-rar-on-the-leukem</item><item key="factor_count">1</item><item key="sample_count">12</item><item key="tags"><item>azurophil granule</item><item>disease</item><item>leukemia</item><item>median</item><item>neutrophil</item><item>protein</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-21550</item><item key="id">3644</item><item key="name">Effect of Protease-resistant PML-RAR&#945; on the leukemogenic potential in a mouse model of Acute Promyelocytic Leukemia</item></item><item><item key="slug">effects-of-gene-scilencing-of-usp2-on-expression-p</item><item key="factor_count">3</item><item key="sample_count">24</item><item key="tags"><item>cell</item><item>genome</item><item>leukemia</item><item>myeloid leukemia</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-20476</item><item key="id">2310</item><item key="name">Effects of gene scilencing of USP2 on expression profiles of HL60 cells</item></item><item><item key="slug">epigenetic-reprogramming-in-relapsed-childhood-all</item><item key="factor_count">2</item><item key="sample_count">14</item><item key="tags"><item>cell</item><item>histone</item><item>leukemia</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-34880</item><item key="id">4381</item><item key="name">Epigenetic reprogramming in relapsed childhood ALL</item></item><item><item key="slug">expression-data-from-a-human-mll-af6-positive-aml</item><item key="factor_count">0</item><item key="sample_count">1</item><item key="tags"><item>bone</item><item>bone marrow</item><item>cell</item><item>chromosome</item><item>leukemia</item><item>line</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-43068</item><item key="id">2479</item><item key="name">Expression data from a human MLL-AF6 positive AML cell line</item></item><item><item key="slug">5-azacytidine-and-entinostat-treatment-of-patients</item><item key="factor_count">2</item><item key="sample_count">24</item><item key="tags"><item>leukemia</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-16625</item><item key="id">3319</item><item key="name">5-azacytidine and entinostat treatment of patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML</item></item><item><item key="slug">acute-myeloid-leukemia-with-cebpa-double-mutations</item><item key="factor_count">2</item><item key="sample_count">38</item><item key="tags"><item>acute myeloid leukemia</item><item>leukemia</item><item>myeloid leukemia</item><item>wt1</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-42064</item><item key="id">2462</item><item key="name">Acute myeloid leukemia with CEBPA double-mutations harbors in 76.8% of cases concomitant molecular mutations with TET2 and GATA2 alterations demonstrating strong prognostic impact</item></item><item><item key="slug">altered-mirna-and-gene-expression-in-acute-myeloid</item><item key="factor_count">2</item><item key="sample_count">12</item><item key="tags"><item>acute myeloid leukemia</item><item>axis</item><item>cell</item><item>inferior</item><item>leukemia</item><item>median</item><item>myeloid leukemia</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-39730</item><item key="id">4542</item><item key="name">Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance</item></item><item><item key="slug">identification-of-protein-kinase-c-beta-2-regulate</item><item key="factor_count">4</item><item key="sample_count">12</item><item key="tags"><item>acute myeloid leukemia</item><item>cell</item><item>dendritic</item><item>leukemia</item><item>line</item><item>myeloid leukemia</item><item>protein</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-54484</item><item key="id">2131</item><item key="name">Identification of protein kinase C beta 2 regulated genes early in dendritic cell differentiation</item></item><item><item key="slug">imatinib-therapy-of-chronic-myeloid-leukemia-resto</item><item key="factor_count">2</item><item key="sample_count">27</item><item key="tags"><item>bone</item><item>bone marrow</item><item>cell</item><item>chronic myeloid leukemia</item><item>class</item><item>genome</item><item>hematopoietic system</item><item>leukemia</item><item>myeloid leukemia</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-33075</item><item key="id">2166</item><item key="name">Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell cycle progression</item></item><item><item key="slug">in-vitro-prednisolone-resistance-signature-in-mll</item><item key="factor_count">1</item><item key="sample_count">43</item><item key="tags"><item>acute lymphoblastic leukemia</item><item>leukemia</item><item>lymphoblastic leukemia</item></item><item key="species">human</item><item key="is_default">False</item><item key="geo_gse_id">E-GEOD-32962</item><item key="id">4266</item><item key="name">In vitro prednisolone resistance signature in MLL-rearranged infant ALL</item></item></data></biogps>
